Patents Assigned to BIOrest Ltd.
-
Patent number: 10265269Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.Type: GrantFiled: May 9, 2018Date of Patent: April 23, 2019Assignee: BIOrest Ltd.Inventors: Yoram Richter, Yehuda Zelig, Omar Elmalak, Dror Eyal
-
Patent number: 10213446Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: GrantFiled: October 24, 2017Date of Patent: February 26, 2019Assignee: BIOrest Ltd.Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
-
Patent number: 9993427Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.Type: GrantFiled: March 14, 2013Date of Patent: June 12, 2018Assignee: BIOrest Ltd.Inventors: Yoram Richter, Yehuda Zelig, Omar Elmalak, Dror Eyal
-
Patent number: 9943481Abstract: A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.Type: GrantFiled: May 25, 2006Date of Patent: April 17, 2018Assignee: BIOrest Ltd.Inventors: Gershon Golomb, Hila Epstein, Eyal Afergan
-
Patent number: 9827254Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: GrantFiled: October 27, 2016Date of Patent: November 28, 2017Assignee: BIOrest Ltd.Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
-
Patent number: 9820998Abstract: The present invention relates to use of bisphosphonate formulations for the treatment and management of HIV/AIDS. The method of the invention comprises administering a formulation comprising an effective amount of a bisphosphonate that specifically inhibits the activity and/or decreases the number of monocytes and/or macrophages, thereby reducing or eliminating HIV reservoirs. The invention also provides a method of complementing an HIV antiviral therapy, such as the highly active antiretroviral therapy (HAART), with a bisphosphonate formulation to improve clinical outcome.Type: GrantFiled: May 15, 2015Date of Patent: November 21, 2017Assignees: BIOREST LTD., OREGON HEALTH & SCIENCE UNIVERSITYInventors: Yoram Richter, Gershon Golomb, Jonah B. Sacha
-
Patent number: 9498488Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.Type: GrantFiled: June 18, 2004Date of Patent: November 22, 2016Assignee: BIOrest LTD.Inventors: Yoram Richter, Elazer R. Edelman, Gershon Golomb, Haim D. Danenberg
-
Publication number: 20140271813Abstract: The present invention relates to a liposomal formulation containing a therapeutic agent and a process for producing the formulation. The liposomal formulation comprises particular characteristics that enhance uniformity and stability of the formulation. The manufacturing process is a novel process that produces a liposomal formulation of a uniform size with many desirable properties that may be independently controlled. Further, the invention relates to a liposome formulation made in accordance with the manufacturing process.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Applicant: BIOrest Ltd.Inventors: Yoram RICHTER, Yehuda ZELIG, Omar ELMALAK, Dror EYAL
-
Patent number: 7048714Abstract: The present invention relates to a medical device and a method of delivering a drug to a target circulation or tissue. The medical device has an expandable portion which is fabricated from a porous elastomeric material with a plurality of voids therein. The voids are loaded with drugs in various formulations. Upon inflation of the expandable portion, the overall diameter increases, the wall thickness decreases and, consequently, the voids are stretched to cause the drug to be expelled from the voids and into the bodily lumen or tissue adjacent to the medical device. The voids include any open volume within the expandable portion capable of containing the drug.Type: GrantFiled: October 30, 2002Date of Patent: May 23, 2006Assignee: BIOrest Ltd.Inventor: Jacob Richter